Victory Capital Management Inc. Has $81.59 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Victory Capital Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 92,891 shares of the biopharmaceutical company's stock after purchasing an additional 3,977 shares during the period. Victory Capital Management Inc. owned approximately 0.09% of Regeneron Pharmaceuticals worth $81,585,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Eudaimonia Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company's stock worth $803,000 after buying an additional 11 shares in the last quarter. Drive Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 12 shares during the period. MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 12 shares during the period. LCM Capital Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 2.5% in the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company's stock valued at $427,000 after buying an additional 12 shares during the period. Finally, Sutton Wealth Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 13 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 2.1 %

Shares of Regeneron Pharmaceuticals stock traded up $19.39 during trading on Friday, reaching $957.00. The stock had a trading volume of 547,373 shares, compared to its average volume of 509,442. The company has a market capitalization of $105.04 billion, a price-to-earnings ratio of 28.27, a P/E/G ratio of 2.69 and a beta of 0.17. The stock has a fifty day moving average price of $943.75 and a two-hundred day moving average price of $896.33. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a current ratio of 6.40, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $10.96 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on REGN shares. UBS Group lifted their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a "buy" rating in a research note on Wednesday, April 17th. Cantor Fitzgerald reissued a "neutral" rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. Barclays lifted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 23rd. Truist Financial reaffirmed a "buy" rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $977.77.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the company's stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,095 shares of company stock worth $9,664,476. Corporate insiders own 8.83% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.